Клиническое значение фактора роста эндотелия сосудов при раке и доброкачественной гиперплазии предстательной железы
Диссертация
По данным отечественных исследователей в структуре онкоурологических заболеваний РПЖ составляет 36% (Двойрин В.В.и соавт., 1996). Необходимо также отметить, что это заболевание является ведущей причиной смерти от злокачественных опухолей у мужчин. В период с 1990 по 1995 гг. прирост заболеваемости РПЖ составил 32,3%. За указанный период времени отмечено увеличение риска заболеть РПЖ на 28,7… Читать ещё >
Содержание
- Список сокращений
- Глава II. ервая
- Литературный обзор
- 1. 1. Статистические данные о раке предстательной железы
- 1. 2. Нормальная и патологическая анатомия предстательной железы
- 1. 3. Классификация рака предстательной железы
- 1. 4. Ангиогенез при раке предстательной железы
- 1. 4. 1. Фактор роста эндотелия сосудов в патогенезе рака предстательной железы
- 1. 4. 2. Ангиогенин в патогенезе рака предстательной железы
- 1. 5. Простатический специфический антиген в диагностике и патогенезе рака предстательной железы
- Глава вторая. материал и методы
- 2. 1. Характеристика больных, включенных в исследование
- 2. 2. Лабораторные методы исследования
- 2. 2. 1. Гистологическое исследование
- 2. 2. 2. Иммуногистохимическое исследование
- 2. 2. 3. Биохимические методы исследования
- 2. 4. Обработка результатов
- 3. 1. Трансабдоминальное и трансректальное ультразвуковое сканирование
- 3. 2. Полифокальная трансперинеальная биопсия предстательной железы под трансректальным ультразвуковым контролем
- 3. 3. Определение стадии рака предстательной железы
- 4. 1. Анализ и оценка достоверности различий концентраций простатического специфического антигена в сыворотке крови больных РПЖ и ДГПЖ
- 4. 2. Изучение клинической значимости фактора роста эндотелия сосудов при раке предстательной железы
- 4. 2. 1. Анализ и оценка достоверности различий уровней экспрессии фактора роста эндотелия сосудов в ткани предстательной железы
- 4. 2. 2. Анализ и оценка достоверности различий концентраций фактора роста эндотелия сосудов в сыворотке крови у больных ДГПЖ и РПЖ
- 4. 2. 3. Связь концентрации VEGF в сыворотке крови с различными клинико-морфологическими характеристиками заболеваний предстательной железы
- 4. 3. Анализ и оценка достоверности различий концентраций ангиогенина в сыворотке крови в исследуемых группах
- 4. 4. Анализ и оценка достоверности содержания общего тестостерона в сыворотке крови больных ДГПЖ и РПЖ
Список литературы
- Аксель Е.М., Матвеев Б. П. Состояние онкоурологической помощи боль-ным в России, 1997 г. // Клиническая онкология. 1999. — Т. 1, № 1. — С. 3−5.
- TNM: Классификация злокачественных опухолей. 5 изд. Под ред. Н. Н. Блинова -СПб.: Эскулап, 1998. с. 145−148
- Гориловский JI.M., Толстова С. С. Рак предстательной железы// Избранные главы гериатрической урологии./ под ред. Л. М. Гориловского.//М., Ньюдиамед. 2000 стр.202−226
- Двойрин В.В., Аксель Е. М., Трапезников Н. Н. Заболеваемость злокачественными новообразованиями и смертность от них населения стран СНГ в 1995 г. — ОНЦ РАМН, 1996. 281с.
- Кушлинский Н.Е. Молекулярные и клеточные маркеры пролиферации, дифферен-цировки, метастазирования и неоангиогенеза при раке предстательной железы. // Избранные главы гериатрической урологии / Под ред. Гориловского Л. М. М.: Ньюдиамед, 2000 с.227−273
- Матвеев Б.П., Бухаркин Б. В., Матвеев В. Б. Рак предстательной железы. М. 1999.- 153с.
- Розен В. Б. Основы эндокринологии. Изд. МГУ, 1994., — 384 с.
- Руководство по урологии: В Зт./ под ред. Н. А. Лопаткина // М., Медицина. 1998.- Т. 3: Рак предстательной железы. 503 с.
- Трапезников Н.Н., Аксель Е. М. Заболеваемость злокачественными новообразованиями и смертность от них населения стран СНГ в 1998г. М. 2000. 179с.
- Abrahamsson PA, di Sant’Agnese PA. Neuroendocrine cells in the human prostate gland. J Androl 1993 Sep-Oct- 14(5):307−9
- Allsbrook W.C., Simms WW Histochemistry of the prostate. Human Pathol 1992 23:297−305
- American cancer Society: Cancer facts and figures, 1996. American cancer society, Atlanta, 1996
- Aprikian AG, Cordon-Cardo C, Fair WR et al. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 1993 Jun 15−71(12):3952−65
- AuerbachR., AuerbachW., Polakowski LAssays for angiogenesis: a review. Pharmacol. Ther., 1991., bl. 51., p. 1−11
- Ayala AG, Ro JY, Babaian R, et al., The prostate capsule: does it exist? Its importance in the staging and treatment of prostatic carcinoma. Am. J. Surg. Pathol 1988,13: 21−27
- Badet J, Soncin F, Guitton JD et al. Specific binding of angiogenin to calf pulmonary artery endothelial cells. Proc Natl Acad Sci U S A1989 Nov- 86(21):8427−31
- Banai S, Shweiki D, Pinson A et al. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc Res. 1994 Aug-28(8): 1176−9
- Barton DP, Cai A, >№ndt К et al., Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res 1997 Sep-3(9): 1579−86
- Bicknell R, &llee BL Angiogenin activates endothelial cell phospholipase C. Proc Natl Acad Sci U S A 1988 Aug-85(16):5961−5
- Bigler SA, Deering RE, Brawer M. K. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol. 1993 Feb-24(2):220−6
- Bischoff J. Cell adhesion and angiogenesis. J Clin Invest. 1995 Feb 1 -99(3):373−6
- Bjork T, Bjartell A, Abrahamsson PA et al. Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 1994−43:427−34
- Bonkhoff H, Stein U, Remberger K. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Arch A Pathol Anat Histopathol. 1993−423(4):291−4.
- Bonkhoff H., Stein U., Remberger K. et al. Multiderectional differentation in the normal, hyperplastic and neoplastic human prostatic: simultaneous demonstration of cell-specific epithelial markers. Human Pathol 1994 25:42−46
- Brawer MK, Deering RE, Brown M et al., Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer. 1994 Feb l-73(3):678−87
- Brawer MK, Meyer GE, Letran J1 et al., measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 52(3): 372−378, 1998
- Brawer MK, Partin A The promise of new serum markers for prostate cancer Contemp. Urol 1999 11(3): 44−75
- Campbell SC. Advances in angiogenesis research: relevance to urological oncology. J Urol. 1997 Nov- 158(5): 1663−74
- Carter H.B., Coffey D.S. The prostate: an increasing medical problem. Prostate, 1990, 16: pp.39−48.
- Chamoux M, Dehouck MP, Fruchart JC Characterization of angiogenin receptors on bovine brain capillary endothelial cells. Biochem Biophys Res Commun 1991 Apr 30- 176(2):833−9
- Chodak GW, Haudenschild C., Gittes R. et al. Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder. Ann Surg. 1980 Dec-192(6) :762−71.
- Chopra V, Dinh TV, Hannigan EV Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Invest 1998- 16(3): 152−9
- Chopra V, Dinh TV, Hannigan EV Serum levels of interleukins, growth factors and angiogenin in patients with endometrial cancer. J Cancer Res Clin Oncol 1997- 123(3): 167−72
- Christensson A., Laurell C.B., Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur.J.Biochem 1990- 194:755−63
- Chung HC, Rha SY, Ahn JB et al. Menstrual state should be considered in determining sero-positivity of soluble angiogenic factors in breast cancer.Int J Mol Med 1998 0ct-2(4):465−470
- Chung LW, Gleave ME, Hsieh JT et al. Reciprocal mesenchymal-epithelial interaction affecting prostate tumour growth and hormonal responsiveness. Cancer Surv. 1991- 11:91 -121.
- Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev. 1996 Jun- 15(2): 165−76.
- Clements J.A. The glandular kallikrein family of enzymes: tissue-specific expression and hormonal regulation. Endocrine Rev. 1989- 10: 393−419
- Cohen P, Peehl DM, Lamson G, et al: Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 73:401−407,1991.
- Cohen RJ, Glezerson G, Taylor LFet al. The neuroendocrine cell population ofthe human prostate gland. J Urol 1993 Aug-150(2 Pt l):365−8
- Coleman M.P., Esteve J., Damiecki P., et al. Trends in cancer incidence and mortality. IARC Scintific Publication № 121 Lyon, 1993
- Collina G, Botticelli AR, Martinelli AM, et al. Sclerosing adenosis of the prostate. Report of 3 cases with electromicroscopy and immunohistochemical study. Histopathology 1992 vol. 20 pp. 505−510
- Cunha GR, Chung LW, Shannon JM et al. Hormone-induced morphogenesis and growth: role of mesenchymal-epithelial interactions. Recent Prog Horm Res. 1983−39:559−98.
- Cunha GR, Donjacour AA, Cooke PS et al., The endocrinology and developmental biology ofthe prostate/ Endocr. Rev 1987, 8:338−362
- Cunha GR. Epithelial-stromal interactions in development of the urogenital tract. Int Rev Cytol. 1976−47:137−94.
- Curran TP, Shapiro R, Riordan JF Alteration of the enzymatic specificity of human angiogenin by site-directed mutagenesis. Biochemistry 1993 Mar9−32(9):2307−13
- Cvetkovic D., Movsas В., Dicker AP et al., Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer. Urology 2001 57: 821−825.
- Czekierdowski A, Zrubek H, Kotarski J Serum angiogenin concentration in women with adnexal tumorsGinekol Pol 2000 Sep-71(9):l 169−72
- D’Alessio G, Di Donato A, Parente A. et al. Seminal RNase: a unique member of the ribonuclease superfamily. Trends Biochem Sci. 1991 Mar- 16(3): 104−6
- Diamandis E.P. New diagnostic applications of prostate-specific antigen. BJU 1997, 79 Suppl. 1,87−91
- Dirix LY, Vermeulen PB, Pawinski A et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer. 1997−76(2):238−43.
- Duque JL, Loughlin KR, Adam RM et al., Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology. 1999 Sep-54(3):523−7.
- Edgren M, Lennernas B, Larsson A et al., Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas. Anticancer Res. 1999 Jan-Feb-19(lB):869−73.
- English HF, Drago JR, Santen RJ. Cellular response to androgen depletion and repletion in the rat ventral prostate: autoradiography and morphometric analysis.Prostate. 1985−7(1):41 -51.
- Eppenberger U, Kueng W, Schlaeppi JM et al. Markers of tumor angiogenesis and proteolysis independently define high- and low- ri Jc subsets of node-negative breast cancer patients. J Clin Oncol 1998 Sep-16(9):3129−36
- Epstein J., Pizov G., Mlsh P.C., Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer (Philad.) 1993., bl. 71., p. 3582−3593
- Eriksson U, Alitalo K. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol. 1999−237:41−57.
- Espana F, Sanchez CJ, Estelles A. et al. Quantitative immunoassay for complexes of prostate-specific antigen with alpha2-macroglobulin. din Chem 1996- 42:545−50
- Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992 Feb-13(l):18−32.
- Ferrara N, Keyt B. fescular endothelial growth factor: basic biology and clinical implications. EXS. 1997−79:209−32.
- FerraraN., Henzel WJ,. Pituitary follicular cells secrete a novel heparin binding factor specific for vascular endothelial cells. Biochem. Diophys Res. Commun 1989,161, 851−859
- Ferrer FA, Miller LJ, Andrawis RI et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol. 1997 Jun-157(6):2329−33
- Fett JW, Strydom DJ, Lobb RR et al.,. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry. 1985 Sep 24−24(20):5480−6
- Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971 Nov 18−285(21):1182−6.
- Folkman J., Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995 Jan-l (l):27−31
- Folkman J., Cotran R. Relation of vascular proliferation to tumor growth. Int. Rev. Exp. Path. 16: 207−248,1976
- Folkman J., Klagsburn M. Angiogenic factors. Science- 1987 bl. 235 pp442−447
- Folkman J., Tumor angiogenesis. 1985 Adv. Cancer Res. 43:175−203
- Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg. 1972 Mar-175(3):409−16.
- Folkman J. What is the evidence that tumours are angiogenesis dependent? J.Natl. Cancer Inst. 1990,82: p.4−6.
- Fortier A.H., Nelson B.J., Grella D.K., et al. Antiangiogenic activity of prostate-specific antigen. J. Natl. Cancer Inst. 1999 Oct 6- 91(19):1635−1640
- Franck-Lissbrant I, Haggstrom S, Damber JE et al. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology. 1998 Feb-139(2):451−6.
- Frank S, Hubner G, Breier G. et al. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem. 1995 May 26−270(21):12 607−13
- Frazier HA, Humphrey PA, Burchette JL, Paulson DP. Immunoreactive prostatic specific antigen in male periurethral glands. J Urol 1992:147:246−8
- Furcht LT. Critical factors controlling angiogenesis: cell products, cell matrix, and growth factors. Lab Invest. 1986 Nov-55(5):505−9
- Garcia-Bustos J., Heitman J., Hall M.N., Nuclear protein localization. Biochim Biophys Acta. 1991 Mar 7−1071(1):83−101.
- Gho YS, Chae CB Anti-angiogenin activity of the peptides complementary to the receptor-binding site of angiogenin. J Biol Chem 1997 Sep 26−272(39):24 294−9
- Gleason DF Classification of prostatic carcinomas. Cancer Chemother. Rep. 1966., Ы. 50., p.125−128
- Gleason DF, Mellinger GT et al. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol. 1974., bl. 111., p.58−64
- Goldberg MA, Schneider TJ. Similarities between the oxygen-sensing mechanisms regulating the expression of vascuJ: r endothelial growth factor and erythropoietin. J Biol Chem. 1994 Feb ll-269(6):4355−9
- Gown AM, fogel AM, Monoclonal antibodies to human intermediate filament proteins: distribution of filament proteins in normal human tissues Am. J. Pathol. 1984 114:309−321
- Griffiths K., Morton MS, Denis L., Certain aspects of molecular endocrinology that relate to the influence of dietary factors on the pathogenesis of prostate cancer. Eur. Urol. 1999, 35:443−455
- Haersley T., Jacobsen GK Microwave processing for immunohistochemical demonstration of proliferating cell nuclear antigen in formalin-fixed and paraffin-embedded tissue. Armis 1994 v. 102.-p395−400
- Haggstrom S, Bergh A, Damber JE. Vascular endothelial growth factor content in metastasizing and nonmetastasizing Dunning prostatic adenocarcinoma. Prostate. 2000 Sep 15−45(l):42−50.
- Hallahan TW, Shapiro R, Strydom DJ, Vallee BL Biochemistry 1992 Sep l-31(34):8022−9 Importance of asparagine-61 and asparagine-109 to the angiogenic activity of human angiogenin.
- Hallahan TW, Shapiro R, Vallee BL. Dual site model for the organogenic activity of angiogenin. Proc Natl Acad Sci U S A1991 Mar 15−88(6):2222−6
- Hanahan D., Folkman J. Patterns and emerging mechanisms ofthe angiogenic switch during tumorigenesis. 1996, Cell. 86: 353−364
- Harper JW, Wlee BL, Mutagenesis of aspartic acid-116 enhances the ribonucleolytic activity and angiogenic potency of angiogenin. Proc Natl Acad Sci U S A1988 Oct-85(19):7139−43
- Hayashi K, Yanagihara T, Hata T Serum angiogenin levels during menstrual cycle andpregnancy. Gynecol Obstet Invest 2000−50(1):7−12
- Heath WF Jr, Moore F, Bicknell R. et al. Modulation of mitogenic stimuli by angiogenin correlates with in vitro phosphatidylinositol bisphosphate synthesis. Proc Natl Acad Sci U S A 1989 Apr-86(8):2718−22
- Hedrick L., Epstein JI Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am. J. Surg. Pathol. 1989 13: 389−396
- Heidtmann HH, Nettelbeck DM, Mingels A, et al: Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer 81:1269−1273,1999
- Houck KA, Leung DW, Rowland AM et al. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem. 1992 Dec 25 -267(36) :26 031 -7
- Hu G, Riordan JF, Wlee BL Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. Proc Natl Acad Sci U S A1994 Dec 6- 91(25):12 096−100
- Hu GF, Chang SI, Riordan JF, Vallee BL An angiogenin-binding protein from endothelial cells. Proc Natl Acad Sci U S A 1991 Mar 15- 88(6): 2227−31
- Hu GF, Riordan JF Angiogenin enhances actin acceleration of plasminogen activation. Biochem Biophys Res Commun 1993 Dec 15- 197(2): 682−7
- Hu GF, Riordan JF, Mee BL A putative angiogenin receptor in angiogenin-responsive human endothelial cells. Proc Natl Acad Sci U S A 1997 Mar 18−94(6):2204−9
- Hu Gf, Xu Cj, Riordan JF Human angiogenin is rapidly translocated to the nucleus of human umbilical vein endothelial cells and binds to DNA. J Cell Biochem 2000 Jan-76(3):452−62
- Icong A.S., Gilham P., Milos J. Cytokeratin and vimentin intermediate filament proteins in benign and neoplastic prostatic epithelium. Histopathology 1988 13:435−442
- Jackson MW, Bentel JM, Tilley WD. Oscular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol. 1997 Jun-157(6):2323−8
- Jakeman LB, Winer J, Bennett GL et al. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest. 1992 Jan-89(l):244−53
- Jeltsch M, Kaipainen A, Joukov V. et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science. 1997 May 30−276(5317): 1423−5.
- Jimi S, Ito K, Kohno K. Modulation by bovine angiogenin of tubular morphogenesis andexpression of plasminogen activator in bovine endothelial cells. Biochem Biophys Res Commun 1995 Jun 15- 211(2): 476−83
- Jones A, Fujiyama C, Turner К et al. Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. BJU Int. 2000 Feb-85(3):276−80
- Jones A., Fujiyama C., Angiogenesis in urological malignancy BJU Int. 1999, 83:535−56
- Kabalin JN, Peehl DM, Stamey TA. Clonal growth of human prostatic epithelial cells is stimulated by fibroblasts. Prostate. 1989−14(3):251−63.
- Kahane H., Sharp JW, Shuman GB et al. Utilization of high molecular cytokeratin on prostate needle biopsies in an independent laboratory. 1995 Urology, 45:981−986.
- Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA. 1993 Nov 15−90(22): 10 705−9.
- Kieser A, Wfeich HA, Brandner G. et al. Mutant p53 potentiates protein kinase С induction of vascular endothelial growth factor expression. Oncogene. 1994 Mar-9(3):963−9
- Kirby R.S., Christmas TJ, Brawer MK. Prostate cancer. London, New York, Toronto: Mosby, 2001 pp. 59−75.
- Klagsburn M, P.A. D"Amore Regulators of angiogenesis. Annu Rev Physiol. 1991−53:217−39.
- Kumar H, Heer K, Lee PWR et al Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res. 1998 May-4(5): 1279−85.
- Lee F, LettrpP., Kumasaca G. et al. The use of transrectal ultrasound in the diagnosis, guided biopsy staging and screening of prostate cancer. Radio Graphics. 1987. bl.7. № 4 pp. 627−644
- Leinonen J, Zhang W-M, Stenman U-H. Complex formation between PSA isoenzymes and protease inhibitors. J Urol 1996:155:1099−103
- Levy AP, Levy NS, WfegnerS. et al. Transcriptional regulation ofthe rat vascular endothelial growth factor gene by hypoxia. J Biol Chem. 1995 Jun 2−270(22):13 333−40
- Li D, Bell J, Brown A et al. The observation of angiogenin and basic fibroblast growth factor gene expression in human colonic adenocarcinomas, gastric adenocarcinomas, and hepatocellular carcinomas. J Pathol. 1994 Feb- 172(2): 171−5
- Li D, Bell J, Brown A. et al. The observation of angiogenin and basic fibroblast growth factor gene expression in human colonic adenocarcinomas, gastric adenocarcinomas, and hepatocellular carcinomas. J Pathol 1994 Feb- 172(2): 171−5
- Li R, Riordan JF, Hu G Nuclear translocation of human angiogenin in cultured human umbilical artery endothelial cells is microtubule and lysosome independent. Biochem Biophys Res Commun 1997 Sep 18−238(2):305−1277
- Madan A, Curtin PT. A 24-base-pair sequence 3' to the human erythropoietin gene contains a hypoxia-responsive transcriptional enhancer. Proc Natl Acad Sci USA. 1993 May l-90(9):3928−32
- Malamitsi-Puchner A, Tziotis J, Tsonou A et al., Serum angiogenin levels in the female from birth to postmenopause. Growth Factors 1999−17(l):75−9
- Marme D. Tumor angiogenesis: the pivotal role of vascular endothelial growth factor. World J Urol. 1996- 14(3): 166−74
- Mazzucchelli R, Montironi R, Santinelli A, et al. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 2000 Sep 15−45(1) pp. 72−79
- McNeal JE Origin and development of carcinoma in the prostate. Cancer 1969 23:24−34
- McNeal JE, Normal histology of the prostate. Am. J. Surg. Pathol 1988,12:619−633
- Mettlin C. Recent developments in the epidemiology of prostate cancer. Eur. J. Cancer, 1997 bl. 33:3,pp. 340−347.
- Mignatti, P., Rifkin, D.B. Plasminogen activators and matrix metallopro-teinases in angiogenesis. Enzyme Protein 1996- 49:117−137.
- Miyake H, Нага I, Yamanaka К et al., Increased angiogenin expression in the tumor tissue and serum of urothelial carcinoma patients is related to disease progression and recurrence. Cancer 1999 Jul 15−86(2):316−24
- Moenner M, Gusse M, Hatzi E. et al. The widespread expression of angiogenin in different human cells suggests a biological function not only related to angiogenesis. Eur J Biochem. 1994 Dec l-226(2):483−90
- Montero S, Guzman C, Cortes-Funes H. et al. Angiogenin expression and prognosis in primary breast carcinoma. Clin Cancer Res 1998 Sep-4(9):2161−8
- Montironi R, Galluzzi CM, Diamanti L. et al. Prostatic intra-epithelial neoplasia. Qualitative and quantitative analyses of the blood capillary architecture on thin tissue sections. Pathol Res Pract. 1993 Jun-189(5):542−8
- Moore F, Riordan JF Angiogenin activates phospholipase С and elicits a rapid incorporation of fatty acid into cholesterol esters in vascular smooth muscle cells. Biochemistry 1990 Jan 9−29(l):228−33
- Moroianu J, Fett JW, Riordan JF, follee BLActin is a surface component of calf pulmonary artery endothelial cells in culture. Proc Natl Acad Sci U S A1993 May l-90(9):3815−9
- Moroianu J, Riordan JF Identification of the nucleolar targeting signal of human angiogenin. Biochem Biophys Res Commun 1994 Sep 30−203(3): 1765−72
- Moul JW. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol. 1999−35(5−6):399−407
- Noden DM. Embryonic origins and assembly of blood vessels. Am Rev Respir Dis. 1989 Oct- 140(4): 1097−103.
- O’Malley FP et al. Usefulness of immunoperoxidase staining with high-molecular-weght cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland. Virch Arch A Pathol Anatom 1990- 417:191)
- Oesterling J. E. Prostate specific antigen: critical assesment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 1991−145:907−23
- Oesterling J.E., Martin S.K., Bergstralh E.J., Low F.C. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993, 269:57−60
- Olson KA, Byers HR, Key ME. et al. Inhibition of prostate carcinoma establishment and metastatic growth in mice by an antiangiogenin monoclonal antibody. Int J Cancer. 2002 Apr 20−98(6):923−9
- Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell. 1993 Dec-4(12):1317−26
- Parkin DM, Pisani P, Ferlay J. Estimates of worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993, 54 pp. 594−606
- Piccoli R, Olson KA, &llee BL et al., Chimeric anti-angiogenin antibody cAb 26-2 °F inhibits the formation of human breast cancer xenografts in athymic mice. Proc Natl Acad Sci U S A1998 Apr 14−95(8):4579−83
- Plouet J., Schilling J., Gospodarowicz D. Isolation and characterization of newly identified endothelial cell mitogen produced by AtT20 cells. EMBO J. 1989, 8, 3801−3807
- Rak J., Mitsuhashi Y., Bayko L. et al., 1995 Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumour angiogenesis/. Cancer Res. 55:4575−80
- Reigman PHJ, Kleassen P., Van der Korpuf JGM. et al. Molecular cloning and characterisation of novel prostate antigen cDNA. Biochem. Biophys Res Commun. 1998- 1555:181−8
- Robins S.P. Collagen crosslinks in metabolic bone disease // Acta Orthop. Scand. 1995. -bl.66.-P. 171−175.
- Rosai J. Male reproductive system: prostate and seminal vesicles. In. Rosai J. (ed.) Ackerman surgical pathology. St. Louis: Mosby year Book, 1996:1244
- Ruijter E., Halvorsen O.J., Servoll e. et al. Molecular genetics and epidemiology of prostate carcinoma// Endocrin. Rev. 1999. fol.20. — p.22−45
- Ruizeveld de Winter JA, Janssen PJ, Sleddens HM et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer Am. J. Pathol. 1994 144 pp. 735−746
- Rybak SM, Fett JW, Yao QZ, et al., Angiogenin mRNA in human tumor and normal cells. Biochem Biophys Res Commun 1987 Aug 14- 146(3): 1240−8
- SakrWA, Grignon DJ Prostate cancer: indicators of aggressiveness. 1997 Eur. Urol 3:15−23
- Sato, Y. Transcription factor ETS- as a molecular target for angiogenesis inhibition. Hum Cell, V11, N 4, P 207−14,1998.
- Schedlich L.J. Bennetts B.H., Morris B.J. Primary structure of human glandular kallikrein gene. DNA1987- 6:429−37
- Senger DR., Galli S J, Dvorak AM et al., Tumour cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219, 983−985
- Seno M, Futami J, Tsushima Y et al. Molecular cloning and expression of human ribonuclease 4 cDNA. Biochim Biophys Acta. 1995 Apr 26−1261(3):424−6
- Shapiro R, Harper JW, Fox EAet al. A179Expression of Met-(-1) angiogenin in Escherichia coli: conversion to the authentic less than Glu-1 protein. Anal Biochem. 1988 Dec-175(2):450−61
- Shibuya M, Ito N, Claesson-Wfelsh L. Structure and function of vascular endothelial growth factor receptor-1 and -2. CurrTop Microbiol Immunol. 1999−237:59−83.
- Shimoyama S, Gansauge F, Gansauge S. et al. Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. Cancer Res 1996 Jun 15−56(12):2703−6
- Shimoyama S, Kaminishi M Increased angiogenin expression in gastric cancer correlated with cancer progression.: J Cancer Res Clin Oncol 2000 Aug-126(8):468−74
- Shimoyama S, Yamasaki K, Kawahara M. et al. Increased serum angiogenin concentration in colorectal cancer is correlated with cancer progression. Clin Cancer Res 1999 May-5(5): 1125−30
- Shweiki D, Itin A, SofFer D. et al. fcscular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992 Oct 29−359(6398):843−5
- Siegal JA, Yu E, Brawer MK. Topography of neovascularity in human prostate carcinoma.Cancer. 1995 May 15−75(10):2545−51
- Silberman MA, Partin AW, feltri RW et al. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate.Cancer. 1997 Feb 15−79(4):772−9.
- Sillman F, Boyce J, Fruchter R. The significance of atypical vessels and neovascularization in cervical neoplasia. Am J Obstet Gynecol. 1981 Jan 15−139(2):154−9
- Soncin F Angiogenin supports endothelial and fibroblast cell adhesion. Proc Natl Acad Sci USA 1992 Mar 15−89(6):2232−6
- Soncin F, Guitton JD, Cartwright T et al., Interaction of human angiogenin with copper modulates angiogenin binding to endothelial cells. Biochem Biophys Res Commun 1997 Jul 30−236(3):604−10
- Sottrup-Jensen L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biof Chem 1989- 264:11 539−42
- Srivastava A., Laidler P., Davies R. et al. The prognostic significance of tumor vascularity in intermediate-thickness (0.76−4.0 mm thick) skin melanoma. A quantitative histologic study. Am J Pathol. 1988 Nov-133(2):419−23.
- Stamey T. A., McNeal J.E., Yemoto С. M. et al., Biological determinants of cancer progression in men with prostate cancer//JAMA- 1999-Vol.281, № 15 -ppl395−1400
- Stamey ТА, Chen ZX, Prestigiacomo A. Serum prostate specific antigen binding alpha 1-antichymotrypsin: influence of cancer volume, location and therapeutic selection of resistant clones. J Urol 1994- 152: 1510−14
- Stamey ТА, Yang N, Hay AR. et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987:317:909−16
- Stanford J. L, Damber J.E., Fair W.R. et al., Epydemiology of prostate cancer/ Prostate cancer/ Ed. Murphy G., Khory S., Partin A., Denis L. p. 544
- Stege R, Grande M, Carlstrom K, et al: Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin Cancer Res 6:160−165,2000.
- Stenman U.-H. Prostate-specific antigen: clinical use and staging an overview. BJU 1997, 79 Suppl. 1,53−60
- StenmanU.-H., Leinonen J., Zhang W.-M. Problems of PSA determinations. Eur. J. Clin Chem Clin Biochem. 1996- 34:735−40
- Stenman UH, Leinonen J, Zhang WM, et al: Prostate-specific antigen. Semin Cancer Biol 9:83−93,1999.
- Strydom DJ, Fett JW, Lobb Rr et al, Amino acid sequence of human tumor derived angiogenin. Biochemistry 1985 Sep 24−24(20):5486−94
- Terman BI, Dougher-fermazen M, Carrion ME. et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun. 1992 Sep 30- 187(3): 1579−86.
- Tsurusaki T, Kanda S, Sakai H, et al., Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer. 1999 Apr-80(l-2):309−13
- Wakui S, Furusato M, Itoh T, et al., Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study. J Pathol. 1992 Nov-168(3):257−62
- Wang MC, Valenzuela LA. Murphy GP, Chu TM. Purification of a human prostate-specific antigen. Invest Urol J 1979 17:159−63
- Wikstrom P, Damber J, BerghA. Role of transforming growth factor-betal in prostate cancer. Microsc Res Tech. 2001 Feb 15−52(4):411−9.
- Wingo PA, Tong T & Bolden S Cancer statistics, 1995. CA Cancer J Clin 45: 8−30.
- Wirth M., Otto T., Rubben H. et al., Prostatekarzinom // Diagnostische und therapeutische Standards in der Urolgischen Oncologie/ Hrsg. Im Auftr. der Deutschen Krebsgesllschaft von L. Wsisbach und K. Miller. 1998 s 92−126
- Woodson K, Tangrea J A, Pollak M. et al., Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res. 2003 Jul 15−63(14):3991−4.
- Wu Y, Saxena SK, Ardelt W et al., A study of the intracellular routing of cytotoxic ribonucleases J Biol Chem 1995 Jul 21 -270(29): 17 476−81
- Yamamoto S, Konishi I, Mandai M et al., Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer. 1997−76(9): 1221−7
- Zhou AM, Tewari PC, Bluestein BI. et al. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays, din Chem 1993- 39: 2483−91